UBS AM’s Enanta Pharmaceuticals ENTA Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q3 | – | Sell |
-149,178
| Closed | -$1.13M | – | 2382 |
|
|
2025
Q2 | $1.13M | Sell |
149,178
-10,319
| -6% | -$62.1K | ﹤0.01% | 2360 |
|
|
2025
Q1 | $880K | Sell |
159,497
-232
| -0.1% | -$1.43K | ﹤0.01% | 2363 |
|
|
2024
Q4 | $918K | Sell |
159,729
-10,886
| -6% | -$104K | ﹤0.01% | 2402 |
|
|
2024
Q3 | $1.77M | Sell |
170,615
-27,597
| -14% | -$361K | ﹤0.01% | 2101 |
|
|
2024
Q2 | $2.57M | Sell |
198,212
-9,877
| -5% | -$133K | ﹤0.01% | 1861 |
|
|
2024
Q1 | $3.63M | Sell |
208,089
-15,980
| -7% | -$211K | ﹤0.01% | 1401 |
|
|
2023
Q4 | $2.11M | Sell |
224,069
-55,153
| -20% | -$514K | ﹤0.01% | 1666 |
|
|
2023
Q3 | $3.12M | Sell |
279,222
-10,852
| -4% | -$175K | ﹤0.01% | 1414 |
|
|
2023
Q2 | $11.7M | Hold |
290,074
| – | – | 0.01% | 909 |
|
|
2023
Q1 | $11.7M | Sell |
290,074
-4,088
| -1% | -$195K | 0.01% | 909 |
|
|
2022
Q4 | $13.7M | Buy |
294,162
+266,993
| +983% | +$12.2M | 0.01% | 844 |
|
|
2022
Q3 | $1.41M | Hold |
27,169
| – | – | ﹤0.01% | 1778 |
|
|
2022
Q2 | $1.28M | Buy |
27,169
+8,510
| +46% | +$462K | ﹤0.01% | 1829 |
|
|
2022
Q1 | $1.33M | Buy |
18,659
+4,979
| +36% | +$324K | ﹤0.01% | 1996 |
|
|
2021
Q4 | $1.02M | Buy |
13,680
+1,349
| +11% | +$106K | ﹤0.01% | 2200 |
|
|
2021
Q3 | $701K | Hold |
12,331
| – | – | ﹤0.01% | 2338 |
|
|
2021
Q2 | $543K | Sell |
12,331
-1,206
| -9% | -$59.1K | ﹤0.01% | 2507 |
|
|
2021
Q1 | $668K | Buy |
13,537
+6,907
| +104% | +$345K | ﹤0.01% | 2281 |
|
|
2020
Q4 | $279K | Sell |
6,630
-4,485
| -40% | -$197K | ﹤0.01% | 2428 |
|
|
2020
Q3 | $509K | Sell |
11,115
-2,539
| -19% | -$123K | ﹤0.01% | 2134 |
|
|
2020
Q2 | $686K | Sell |
13,654
-1,161
| -8% | -$60.1K | ﹤0.01% | 1974 |
|
|
2020
Q1 | $762K | Buy |
14,815
+1,811
| +14% | +$96.5K | ﹤0.01% | 1801 |
|
|
2019
Q4 | $803K | Buy |
13,004
+1,385
| +12% | +$85.9K | ﹤0.01% | 2030 |
|
|
2019
Q3 | $698K | Sell |
11,619
-1,385
| -11% | -$103K | ﹤0.01% | 2126 |
|
|
2019
Q2 | $1.1M | Buy |
13,004
+815
| +7% | +$73.3K | ﹤0.01% | 1840 |
|
|
2019
Q1 | $1.16M | Buy |
12,189
+3,469
| +40% | +$311K | ﹤0.01% | 1761 |
|
|
2018
Q4 | $618K | Sell |
8,720
-7
| -0.1% | -$537 | ﹤0.01% | 1907 |
|
|
2018
Q3 | $746K | Sell |
8,727
-2,088
| -19% | -$209K | ﹤0.01% | 1916 |
|
|
2018
Q2 | $1.25M | Buy |
10,815
+3,595
| +50% | +$359K | ﹤0.01% | 1718 |
|
|
2018
Q1 | $584K | Buy |
7,220
+3,120
| +76% | +$240K | ﹤0.01% | 1975 |
|
|
2017
Q4 | $241K | Buy |
+4,100
| New | +$205K | ﹤0.01% | 2215 |
|
Other funds holding ENTA
FCM
KAM
CC
UBS AM's ENTA Position: Q3 2025 in Review
UBS AM sold out of Enanta Pharmaceuticals (ENTA) in Q3 2025, closing a stake of 149,178 shares — an estimated $1.13M sold.
UBS AM first reported a position in ENTA in Q4 2017 and held it in 31 quarters. The position peaked at $13.7M in Q4 2022. 121 funds tracked by Wall St. Rank hold ENTA as of Q3 2025.
- UBS AM reported no remaining Enanta Pharmaceuticals position as of Q3 2025 after selling out during the quarter.
- UBS AM sold 149,178 Enanta Pharmaceuticals shares in Q3 2025, an estimated $1.13M.
- UBS AM first reported a position in Enanta Pharmaceuticals in Q4 2017 and held it in 31 quarters.
- UBS AM's Enanta Pharmaceuticals position peaked at $13.7M in Q4 2022.
- 121 funds tracked by Wall St. Rank held Enanta Pharmaceuticals as of Q3 2025.
Based on UBS AM's 13F filing for Q3 2025, filed 14 Nov 2025.